Moderna to Supply Additional Vaccine Doses for Low Income Countries, Build Plant in Africa

Posted by ISPE Boston
On October 14, 2021

Gavi, the Vaccine Alliance has exercised its option to purchase an additional 176.5 million doses of the Moderna COVID-19 vaccine for the COVAX Facility. Of these additional doses, 116.5 million doses are expected to be delivered in the first quarter of 2022 and 60 million doses are expected to be delivered in the second quarter of 2022. […]

Neumora Launches with $500M in Funding

Posted by ISPE Boston
On October 14, 2021

Watertown biotech Neumora Therapeutics, a clinical-stage company pioneering precision medicines for brain diseases, has announced its launch. Neumora was founded as a response to the lack of targeted, effective medicines for brain diseases and the high neuroscience drug development failure rate and has raised over $500 million, including a $100 million equity investment from Amgen. […]

Ground-Breaking GSK Malaria Vaccine Receives WHO Endorsement

Posted by ISPE Boston
On October 7, 2021

The World Health Organization has recommended GSK’s malaria vaccine RTS,S for broader deployment to reduce childhood illness and deaths from malaria in children living in sub-Saharan Africa and other regions with moderate to high transmission. RTS,S is the first and only malaria vaccine to have been shown in pivotal long-term clinical trials to significantly reduce […]

Merck to Acquire Acceleron for $11.5 Billion

Posted by ISPE Boston
On October 4, 2021

Merck and Acceleron Pharma have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Acceleron for $180 per share in cash for an approximate total equity value of $11.5 billion. The transaction is expected to close in the fourth quarter of 2021. Acceleron is focused on harnessing the power of the […]

Chapter Member Anniversaries: October 2021

Posted by ISPE Boston
On October 4, 2021

Please congratulate the following members celebrating milestone anniversaries in October 2021. Their dedication to ISPE, the Boston Area Chapter and the industry is applauded! Over Thirty Years Peter M. Solazzo, ModWave LLC Over Twenty Years Mark S. Caswell, Lonza Biologics Inc William G. Devine, Pharma-Tech Services Ric Feldt, Jeff Smith & Associates Dr. Michael T. […]

Welcome New Members September 2021!

Posted by ISPE Boston
On October 4, 2021

We would like to introduce the Members who joined ISPE in September 2021, welcome them to the Chapter and encourage them (and all of our members) to take advantage of the many professional development, networking and information resources available through ISPE. Fellow ISPE members are a terrific resource for help with everyday professional challenges. And […]

EDEI Debuts at Product Show

Posted by Eni Adedokun El-Wadi
On September 30, 2021

The EDEI (Ethnocultural Diversity, Equity, and Inclusion) Committee held its first-ever Product Show event this year. We had a great time networking with other Product Show attendees and sharing stories of Product Show experiences over a few drinks. For several team members, this was the first in-person meeting after months of virtual sessions, with some […]

Product Show 2021 – Into the Unknown!

Posted by Jesse McLaughlin
On September 30, 2021

Have you ever seen the movie “Frozen”? There’s a song that Elsa sings called “Into the Unknown” and that’s what it felt like getting ready for the Product Show this year. We had no idea what to expect but I’m here to tell you, this year’s Product Show did not disappoint! For many of us […]

Laronde Attracts $440M for Endless RNA

Posted by ISPE Boston
On September 23, 2021

Laronde, the Cambridge startup pioneering a novel, engineered form of RNA they call Endless RNA™ (eRNA), has raised $440 Million in a Series B Financing. eRNA can be programmed to express therapeutic proteins inside the body. The financing round included the company’s founder, Flagship Pioneering, among other investors. Ribonucleic acids, or RNAs, play a significant role in biology. […]

Vertex and Arbor Partner to Develop Novel Engineered Cell Therapies

Posted by ISPE Boston
On September 22, 2021

Vertex Pharmaceuticals and Arbor Biotechnologies have announced a new collaboration to enhance efforts in developing ex vivo engineered cell therapies using Arbor’s proprietary CRISPR gene-editing technology for select diseases. The new agreement builds upon the companies’ first partnership established in 2018. Under this new partnership, Vertex will receive rights to use Arbor’s technology to research and develop ex […]

Page 42 of 117«‹40 414243 44 ›»